Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

Ava Grace 2025 Nov 08, 00:00

AI Funding Concerns Trigger Tech Stock Sell-Off

Sophia Claire 2025 Nov 08, 00:00

Gold Price Outlook: Currency Devaluation Trade Still Alive

Liam James 2025 Nov 08, 00:00

JPMorgan Sees Buying Opportunity Amid Market Jitters

Emma Rose 2025 Nov 07, 00:00

The Fed's Balance Sheet Expansion: Drivers and Potential Implications

Noah Lee 2025 Nov 07, 00:00

LME Aluminum Bull Run: Is a Structural Deficit Emerging?

Frances Wang 2025 Nov 06, 16:00

Gold and silver prices are up: what's happening to Gold (XAU/USD) and XAG?

Frances Wang 2025 Nov 06, 16:00

Nvidia Competitors Analysis (2026), NVDA Stock: AMD, Intel, Qualcomm, AVGO

Frances Wang 2025 Nov 05, 16:00

Crypto market update: Ethereum price drops, Bitcoin price falls below $104K

Frances Wang 2025 Nov 05, 16:00

XRP price prediction: XRP rebounds, Is XRP expected to go high?

Frances Wang 2025 Nov 05, 16:00

Tesla stock jumps 4% today: what’s driving the TSLA share price?

Latest news

Show more
Sophia Claire 2025 Nov 09, 05:50

Navigating Uncertainty: Liquidity-Driven Markets and Policy Reflections

Sophia Claire 2025 Nov 09, 05:50

Bitcoin Hype Cycle: Galaxy Digital Foresees Potential Return to Former Glory

Sophia Claire 2025 Nov 09, 04:10

Re7 Labs xUSD Depeg Report: Analysis and Financial Impact

Emma Rose 2025 Nov 09, 01:40

DeFi's Natural Selection: Lessons from Stream Finance & Aave's Resilience

Emma Rose 2025 Nov 09, 01:40

Bitcoin Dominance Fluctuations: A Harbinger of Altcoin Season?

Ava Grace 2025 Nov 09, 00:30

NFT Market Weekly Report: Trading Volume and User Engagement Decline

Noah Lee 2025 Nov 09, 00:10

XRP's Misunderstood Potential: Building a Global Financial Infrastructure

Emma Rose 2025 Nov 08, 23:10

Bitcoin Power Law Suggests Potential Surge to $142,000 Amidst Analyst Revisions

Info

Spread

1.0690

Spread (%)

1.0415 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

14:31 - 20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

24800575488

Shares Outstanding

240455450

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.64

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Nov 06, 16:00

How to start cryptocurrency trading: how to trade BTC Price (BTC/USD) CFDs?

Ghko B 2025 Nov 06, 16:00

Xom Stock Forecast: What is the future forecast for XOM?

Ghko B 2025 Nov 06, 16:00

Top Australian Shares: Argo Investments, BHP, CBA stock and more

Trustpilot